Sean McCutcheon
Stock Analyst at Raymond James
(4.44)
# 1,296
Out of 4,587 analysts
40
Total ratings
42.9%
Success rate
39.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sean McCutcheon
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTH Faeth Therapeutics | Initiated Coverage: Buy | $56 | $28.99 | +93.17% | 1 | Jul 31, 2026 | |
| RLAY Relay Therapeutics | Maintained: Buy | $19 → $26 | $18.76 | +38.59% | 2 | May 19, 2026 | |
| ENGN enGene Therapeutics | Maintained: Buy | $27 → $4 | $1.73 | +131.21% | 5 | May 8, 2026 | |
| CMPX Compass Therapeutics | Downgraded: Hold | n/a | $1.89 | - | 3 | Apr 28, 2026 | |
| VIR Vir Biotechnology | Maintained: Buy | $12 → $19 | $8.63 | +120.16% | 4 | Feb 24, 2026 | |
| BBOT BridgeBio Oncology Therapeutics | Initiated Coverage: Buy | $24 | $8.28 | +189.86% | 1 | Jan 9, 2026 | |
| RVMD Revolution Medicines | Maintained: Buy | $72 → $76 | $188.17 | -59.61% | 2 | Oct 17, 2025 | |
| BDTX Black Diamond Therapeutics | Maintained: Buy | $11 | $1.65 | +568.69% | 2 | Sep 10, 2025 | |
| RGNX REGENXBIO | Reiterated: Buy | $29 | $9.83 | +195.02% | 5 | Sep 5, 2025 | |
| XNCR Xencor | Maintained: Buy | $40 | $20.25 | +97.53% | 1 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $27.11 | n/a | 4 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $63.81 | n/a | 3 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $743.37 | n/a | 3 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $65 | $15.07 | n/a | 1 | Jul 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $86 | $18.49 | n/a | 3 | Jun 13, 2025 |
Faeth Therapeutics
Jul 31, 2026
Initiated Coverage: Buy
Price Target: $56
Current: $28.99
Upside: +93.17%
Relay Therapeutics
May 19, 2026
Maintained: Buy
Price Target: $19 → $26
Current: $18.76
Upside: +38.59%
enGene Therapeutics
May 8, 2026
Maintained: Buy
Price Target: $27 → $4
Current: $1.73
Upside: +131.21%
Compass Therapeutics
Apr 28, 2026
Downgraded: Hold
Price Target: n/a
Current: $1.89
Upside: -
Vir Biotechnology
Feb 24, 2026
Maintained: Buy
Price Target: $12 → $19
Current: $8.63
Upside: +120.16%
BridgeBio Oncology Therapeutics
Jan 9, 2026
Initiated Coverage: Buy
Price Target: $24
Current: $8.28
Upside: +189.86%
Revolution Medicines
Oct 17, 2025
Maintained: Buy
Price Target: $72 → $76
Current: $188.17
Upside: -59.61%
Black Diamond Therapeutics
Sep 10, 2025
Maintained: Buy
Price Target: $11
Current: $1.65
Upside: +568.69%
REGENXBIO
Sep 5, 2025
Reiterated: Buy
Price Target: $29
Current: $9.83
Upside: +195.02%
Xencor
Aug 7, 2025
Maintained: Buy
Price Target: $40
Current: $20.25
Upside: +97.53%
Jul 24, 2025
Reiterated: Hold
Price Target: n/a
Current: $27.11
Upside: n/a
Jul 17, 2025
Maintained: Hold
Price Target: n/a
Current: $63.81
Upside: n/a
Jul 17, 2025
Maintained: Hold
Price Target: n/a
Current: $743.37
Upside: n/a
Jul 11, 2025
Initiated Coverage: Buy
Price Target: $65
Current: $15.07
Upside: n/a
Jun 13, 2025
Maintained: Buy
Price Target: $86
Current: $18.49
Upside: n/a